ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

KRAS Mutant Inhibitor BBO-11818

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

Furthest: phase 1, since Apr 1, 20251 company-led study, 1 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)11 open or runningphase 1since Apr 1, 2025Apr 1, 2025Aug 2027phase 1 · NCT06917079

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 1, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06917079 · 665 planned · United States, Australia

Ahead

  1. Aug 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06917079

TargetBeta

KRAS →read by rule
“An orally bioavailable non-covalent inhibitor of both the active, guanosine triphosphate (GTP)-bound (ON) form and the inactive, guanosine diphosphate (GDP)-bound (OFF) form of multiple oncogenic KRAS substitution mutations, including KRAS G12D, G12V and G12X, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06917079Carcinoma, Non-Small-Cell Lung · United States, Australia1RecruitingAug 2027665

How it is read

Names in the registry

  • “BBO-11818”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.